Breast Cancer Research

We have a long-standing program of pre-clinical breast cancer research within the Kolling Institute.

Our work mainly focuses on a specific type of breast cancer called triple-negative breast cancer. This typically affects women at a younger age. It is more difficult to treat and has less favourable outcomes than other types of breast cancer.

Our team is working to develop new ways to predict how the disease will progress and new drugs to overcome resistance to chemotherapy and radiotherapy. Our research is also aimed at developing new treatments to replace chemotherapy.

Lead

Professor Rob Baxter

Emeritus Professor, Medicine,
Northern Clinical School,
Faculty of Medicine and Health
Fellow of the Australian Academy of Science
Fellow of the Australasian Association of Clinical Biochemists

People

Dr Janet Martin

Senior Research Fellow (honorary)

Ms Hasanthi de Silva

Senior Research Assistant

Network

Current and recent collaborators:

Medical Oncology: Professor Fran Boyle, Mater Hospital and University of Sydney

Cancer Immunology: Dr Lisa Hedger, Faculty of Science, University of Technology, Sydney

Pharmacy: Dr Pegah Varamini, University of Sydney

Chemistry: Dr Markus Müllner, Professor Richard Payne, University of Sydney

Projects

Our research program in triple-negative breast cancer has three main aims:

To develop a new method of predicting how the disease will progress, based on measuring different proteins or biomarkers produced by the tumours
To develop a new drug to overcome resistance to chemotherapy and radiotherapy
To develop a new combination drug treatment to replace chemotherapy and avoid its side-effects.

Publications

https://scholar.google.com/citations?user=AMeTRxAAAAAJ&hl=en

http://sydney.edu.au/medicine/people/academics/profiles/robert.baxter.php#publications-by-year